新诊断不利中危前列腺癌患者PSMA PET/CT检查适宜性——迈向基于肿瘤体积的风险分层
本研究重新评估PSMA PET/CT在不列中危前列腺癌中的诊断价值,并验证荷兰前列腺癌网络(PCNN)亚分类。分析接受PSMA PET/CT的男性患者,评估转移性疾病发生率及其与PCNN亚组的相关性。结果显示12.4%的患者发现转移性疾病,较高PCNN亚组与转移潜能增加相关,低转移潜能病例的比值比显著较低(OR 0.19,95%CI 0.06-0.62;p=0.01),PCNN亚分类可减少48.1%的扫描负担。
要点
- 12.4%的不利中危前列腺癌患者经PSMA PET/CT发现转移性疾病。
- 较高PCNN亚组与转移潜能增加相关,低转移潜能病例OR为0.19(95%CI 0.06-0.62)。
- PCNN亚分类可减少48.1%的扫描负担。
核心结论
- 研究结果重申PSMA PET/CT在不列中危前列腺癌中的诊断价值,并验证PCNN亚分类可减少48.1%的扫描负担。
研究设计与样本
- 本研究分析接受PSMA PET/CT的男性患者,评估转移性疾病发生率及其与PCNN亚组的相关性。
主要发现
- 12.4%的患者发现转移性疾病。
- 较高PCNN亚组与转移潜能增加相关;低转移潜能病例的比值比显著较低(OR 0.19,95%CI 0.06-0.62;p=0.01)。
关键数值与推荐
- 低转移潜能病例的OR为0.19(95%CI 0.06-0.62;p=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. SUBJECTS/METHODS: Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups. RESULTS: Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01). CONCLUSIONS: Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.
引用
- Hagens MJ, Luining WI, Boevé LMS, et al. The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification. Prostate Cancer Prostatic Dis. 2024. PMID: 39313655. doi:10.1038/s41391-024-00899-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。